OverviewCommunityWorkflowResearchCollaborate
Learn Before
  • Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

    Concept icon
Relation

Results - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

  • Specific antibody responses to RBD and neutralizing antibodies to live SARS-CoV-2 and pseudovirus
  • Specific T-cell responses
  • Adverse reactions by time

0

1

Updated 2020-10-07

Contributors are:

YL
Yeji Lee
🏆 2

Who are from:

SC
Smith College
🏆 2

References


  • Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Tags

SARS-CoV-2 (COVID-19)

Biomedical engineering

Biomedical Sciences

Related
  • Methods - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

    Concept icon
  • Discussion on Immunogenicity and safety of a recombinant ad-5 COVID-19 vaccine

  • Limitations of Immunogenicity and Safety of a Recombinant ad-5 COVID-19 vaccine

Learn After
  • Specific T-cell responses - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

    Concept icon
  • Specific antibody responses to RBD and neutralizing antibodies to live SARS-CoV-2 and pseudovirus - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

    Concept icon
  • Adverse reactions by time - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

    Concept icon
logo 1cademy1Cademy

A shared prerequisite knowledge graph

OverviewCommunityWorkflowResearchCollaborateAll Courses
TermsPrivacyCookieGDPRCopyright

Contact Us

onecademy.info@gmail.com

Follow Us




© 1Cademy 2026
Opens in a new tab